SLStefan Lakämper

Stefan Lakämper

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stefan Lakämper has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Commonly experienced acute and cumulative 8-hour sleep loss differentially affect simulated driving during a night-time to early-morning commute: a randomized controlled crossover trial

    by Stefan Lakämper, Michael Scholz, Thomas Kraemer, Hans-Peter Landolt, Kristina Keller

    Sleep loss is a major contributor to traffic accidents, yet the differential effects of two common real-world patterns of sleep loss, acute total sleep deprivation and cumulative sleep restriction producing an equivalent 8-h sleep loss, on vehicle control remain poorly quantified. Leveraging tightly controlled sleep manipulation and highly immersive driving simulation, we directly compared the effects of different patterns of sleep loss under naturalistic driving conditions. Twenty healthy male participants completed a randomized within-subject crossover sleep design, comprising normal sleep, cumulative sleep restriction (four nights 2 h reduced sleep per night), and acute total sleep deprivation (one night without sleep), each followed by a simulated nighttime-to–early-morning commute. Acute total sleep deprivation produced pronounced impairments in vehicle control. Most prominently, lateral control deteriorated within 4–6 min under acute deprivation, with impairments comparable to those reported at high blood alcohol concentrations (1.2–1.4 g/L). Steering instability and integrated driving performance showed convergent deterioration. In contrast, cumulative sleep restriction resulted in smaller and less consistent changes, while vigilance task performance and speed variability were comparatively preserved across all conditions. Despite graded increases in subjective sleepiness across conditions, cumulative sleep restriction produced only limited changes in driving performance, whereas acute sleep deprivation produced a disproportionate risk to driving safety by selectively and rapidly degrading operational vehicle control. These findings, obtained under ecologically relevant sleep and driving conditions, underscore functional and potentially physiological differences between acute and cumulative sleep loss and, practically, highlight the importance of distinguishing between them when considering sleep-loss–related driving impairment and safety risk. Clinical Trials–name, URL, and registration: Clinical Trial name: Study of Identification of Metabolomics-based Sleepiness Markers for Risk Prevention and Traffic Safety—ClinicalTrials.gov Identifier NCT05585515, released on 18.10.2022, https://clinicaltrials.gov/study/NCT05585515; Swiss National Clinical Trial Portal SNCTP000005089, registered on 12.08.2022, https://www.humanforschung-schweiz.ch/de/studiensuche/studien-detail/58930. IRB Statement: This study was approved by the local ethics committee (Kantonale Ethikkommission Zürich, reference number 2022–01273). No identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. Informed consent materials are available from the corresponding author on request. We confirm all methods were performed in accordance with the Declaration of Helsinki and its later amendments.


  • Open Access

    Validating a novel driving simulation-based MWT against the standard MWT in an OSA-cohort challenged by CPAP-withdrawal (DS-MWT2) – Protocol for a monocentric, controlled, randomized, crossover trial

    by Veronika Gambin, Nan Li, Esther Irene Schwarz, Kristina Keller, Stefan Lakämper

    Background: Excessive daytime sleepiness (EDS) is a major yet under-recognized contributor to road traffic accidents. Traditional diagnostic tools, such as the Maintenance of Wakefulness Test (MWT), assess wakefulness under passive conditions but may not accurately reflect real-world driving risks. To address this gap, we have piloted a Driving Simulation–based MWT (DS-MWT), designed to evaluate sleepiness in an ecologically valid driving scenario. The present study aims to validate the novel DS-MWT against the classical MWT in a functionally relevant cohort of patients with obstructive sleep apnoea (OSA). Methods: The present monocentric, randomized, controlled, within-subject crossover trial will include 54 participants: 36 patients with OSA undergoing ≥ 7-day CPAP withdrawal (W) or continuation (C), and 18 healthy controls. The study employs a well-established CPAP-withdrawal model in patients with prior optimal treatment adherence to transiently induce EDS under controlled conditions. A healthy control group is included to enable between-group comparisons. The primary expected outcome is the difference in mean latencies between MWT and DS-MWT, determined during four standardized test sessions per condition. Secondary exploratory outcomes are defined as the presence, direction, and magnitude of differences or correlations between treatment status (CPAP withdrawal vs. continuation) and driving performance metrics (e.g., lateral position, speed, lane departures, etc.), EEG and eye-tracking features, subjective sleepiness scores, at-home polysomnography (PSG) parameters, and metabolomic biomarkers (saliva, exhaled breath and dried blood spots). Data will be analyzed using linear mixed models, repeated-measures ANOVA, and predictive modeling with cross-validation. Discussion: This trial addresses a critical limitation in sleep and traffic medicine by introducing a realistic, supposedly more ecologically valid alternative to standard sleepiness assessment tools. The DS-MWT may enhance clinical decision-making regarding fitness to drive (FTD) and provide a framework for identifying physiological and behavioral markers of sleepiness in realistic conditions. Trial registration: ClinicalTrials.gov Identifier: NCT06872593 , released on 12.03.2025, https://clinicaltrials.gov/study/NCT06872593 . Swiss National Clinical Trial Portal SNCTP000006301, released on 19.03.2025, https://www.humanforschung-schweiz.ch/en/trial-search/study-detail/66469 .

  • Open Access

    Effects of Sleep Restriction and Sleep Deprivation on Behaviorally Relevant Electrophysiological Signal Patterns Revealed by Interpretable Machine Learning

    by Benjamin Stucky, Michael Scholz, Stefan Lakämper, Kristina Keller, Thomas Kraemer, Hans-Peter Landolt

    Acute and accumulated sleep loss differently impair alertness and cognition, yet context-aware biomarkers remain elusive. We applied interpretable machine learning to multimodal physiological data collected under controlled conditions to identify reliable biomarkers. In a within-participant, cross-over design, 47 healthy men (mean age: 23.7 ± 2.8 years) underwent 5-min waking electroencephalographic (EEG) recordings with eyes open after normal sleep (8 h sleep opportunity), sleep restriction (four nights, 6 h sleep opportunity), and acute total sleep deprivation (0 h sleep opportunity). Recordings included six EEG derivations, and simultaneous heart rate and eye-movement data. A subsample (n = 20) completed subjective sleepiness assessments, psychomotor vigilance tests, and a 22-min immersive driving simulation with EEG monitoring.,Classification models using participant-stratified cross-validation achieved 75% accuracy in distinguishing normal sleep from total deprivation despite varied timepoints and cognitive loads. Key EEG features included frontal theta, alpha and beta power, fronto-central mutual information, and a novel biomarker, frontal Hilbert envelope root mean square of successive differences, indicative of altered cortical excitability. Consistent with differential cognitive impairments, sleep restriction showed a distinct physiological signature compared to control and sleep deprivation, particularly in eye movements and heart rate variability. Importantly, the top-10 features showed subjective and behavioral relevance, explaining up to 37% of the variance in subjective sleepiness, vigilant attention and driving performance.,In conclusion, findings demonstrate the feasibility of interpretable machine learning for identifying electrophysiology-based biomarkers of sleep-related cognitive impairment and underscore the need for diverse samples and tasks to enhance generalizability.


  • Open Access

    Validating a novel driving simulation-based MWT against the standard MWT in an OSA-cohort challenged by CPAP-withdrawal (DS-MWT2) – Protocol for a monocentric, controlled, randomized, crossover trial

    by Veronika Gambin, Nan Li, Esther Irene Schwarz, Kristina Keller, Stefan Lakämper

    Background: Excessive daytime sleepiness (EDS) is a major yet under-recognized contributor to road traffic accidents. Traditional diagnostic tools, such as the Maintenance of Wakefulness Test (MWT), assess wakefulness under passive conditions but may not accurately reflect real-world driving risks. To address this gap, we have piloted a Driving Simulation–based MWT (DS-MWT), designed to evaluate sleepiness in an ecologically valid driving scenario. The present study aims to validate the novel DS-MWT against the classical MWT in a functionally relevant cohort of patients with obstructive sleep apnoea (OSA). Methods: The present monocentric, randomized, controlled, within-subject crossover trial will include 54 participants: 36 patients with OSA undergoing ≥ 7-day CPAP withdrawal (W) or continuation (C), and 18 healthy controls. The study employs a well-established CPAP-withdrawal model in patients with prior optimal treatment adherence to transiently induce EDS under controlled conditions. A healthy control group is included to enable between-group comparisons. The primary expected outcome is the difference in mean latencies between MWT and DS-MWT, determined during four standardized test sessions per condition. Secondary exploratory outcomes are defined as the presence, direction, and magnitude of differences or correlations between treatment status (CPAP withdrawal vs. continuation) and driving performance metrics (e.g., lateral position, speed, lane departures, etc.), EEG and eye-tracking features, subjective sleepiness scores, at-home polysomnography (PSG) parameters, and metabolomic biomarkers (saliva, exhaled breath and dried blood spots). Data will be analyzed using linear mixed models, repeated-measures ANOVA, and predictive modeling with cross-validation. Discussion: This trial addresses a critical limitation in sleep and traffic medicine by introducing a realistic, supposedly more ecologically valid alternative to standard sleepiness assessment tools. The DS-MWT may enhance clinical decision-making regarding fitness to drive (FTD) and provide a framework for identifying physiological and behavioral markers of sleepiness in realistic conditions. Trial registration: ClinicalTrials.gov Identifier: NCT06872593 , released on 12.03.2025, https://clinicaltrials.gov/study/NCT06872593 Swiss National Clinical Trial Portal SNCTP000006301, released on 19.03.2025, https://www.humanforschung-schweiz.ch/en/trial-search/study-detail/66469

  • Open Access

    Impact of drug holidays on simulated driving performance in adults with ADHD: a study protocol for a randomized crossover trial

    by Nan Li, Veronika Gambin, Boris Quednow, Pascal Burger, Ana Buadze, Benjamin Offenhammer, Kristina Keller, Stefan Lakämper

    Background Attention deficit hyperactivity disorder (ADHD) is linked to an increased risk of traffic accidents, primarily due to inattentiveness. Both stimulant and nonstimulant medications have proven effective in reducing ADHD symptoms, thereby supporting safe driving under well-managed treatment plans. In pediatric care, “drug holidays”, i.e. short-term interruptions in medication, are commonly used to mitigate side effects without compromising therapeutic efficacy. Drug holidays have been quickly adopted by adults and are increasingly recognized and accepted within therapeutic frameworks. Although stimulant treatment has been shown to enhance driving performance, no studies have yet directly investigated the effects of drug holidays on adult drivers. This study protocol aims to examine the impact of stimulant drug holidays on driving performance in adults with ADHD using a driving simulation. Methods This study presents a protocol for a monocentric, within-subjects, participant-randomized, observer-blinded crossover trial of a cohort of ADHD patients practicing drug holidays. Eligible participants are randomly assigned to either Group 1 (M-M-D) or Group 2 (M-D-M), completing a test sequence in different orders of medicated (M) and unmedicated (“drug holiday“, D) states to assess the effects of medication withdrawal on driving performance. The primary outcome is the Integrated Driving Score (IDS), calculated as a summation of Z-scores of key driving parameters during a 40-minute monotonous car-following task. Data will be analyzed using Linear Mixed Models (LMM). Secondary exploratory outcomes include physiological metrics from eye-tracking and electroencephalography (EEG), subjective psychometric assessments, and pharmacokinetic validation via medication levels in blood, saliva, urine, and exhaled breath. Discussion This study investigates the functional consequences of stimulant drug holidays on driving safety in adults with ADHD. While the findings are specific to the simulated context, they will potentially yield a novel evidence-based avenue to guide safety-related clinical decisions for patients considering or practicing drug holidays, potentially complementing future fitness-to-drive guidelines. Trial registration : ClinicalTrials.gov, NCT06910605. Registered 04 April 2025, https://clinicaltrials.gov/study/NCT06910605

  • Open Access

    Effects of acute or cumulative 8-hour sleep loss on simulated driving in a naturalistic, monotonous night-time setting: a randomized, controlled, crossover trial

    by Stefan Lakaemper, Michael Scholz, Thomas Kraemer, Hans-Peter Landolt, Kristina Keller

    Sleep loss is a major contributor to traffic accidents, yet the differential effects of acute versus cumulative 8-hour sleep loss on vehicle control remain poorly quantified. This study leveraged tightly controlled sleep manipulation together with highly immersive driving simulation to directly compare sleep-loss modes under naturalistic driving conditions. To evaluate subjective sleepiness, driving performance and vigilance, healthy male participants completed a randomized within-subject crossover sleep design, comprising normal sleep, cumulative sleep restriction (four nights with 2 h reduced sleep per night), and acute total sleep deprivation (one night without sleep), each followed by a simulated nighttime-to-early-morning driving protocol segmented into modules. Linear mixed-effects models evaluated condition effects and time-on-task dynamics. Acute total sleep deprivation produced pronounced impairments in vehicle control. Most prominently, lateral control deteriorated rapidly under acute deprivation, with effect magnitudes comparable to those reported at high blood alcohol concentrations. Steering instability and integrated driving performance showed convergent deterioration. In contrast, cumulative sleep restriction resulted in smaller and less consistent changes, while vigilance task performance and speed variability were comparatively preserved across all conditions. Despite increased subjective sleepiness, cumulative sleep loss provoked relatively small changes in driving performance, whereas acute sleep deprivation produced a disproportionate risk to driving safety by selectively and rapidly degrading operational vehicle control. These findings, obtained under ecologically relevant sleep and driving conditions, underscore functional and potentially underlying physiological differences between acute and cumulative sleep loss and, practically, highlight the importance of distinguishing between them when considering sleep-loss-related driving impairment and safety risk.

  • Capturing sleep accidents in driving simulation as a promising tool to assess excessive daytime sleepiness with high ecological validity—a pilot study

    by Melissa Pisteljic, Kristina Keller, Stefan Lakämper

    Melissa Pisteljic, Kristina Keller, Stefan Lakämper; Capturing sleep-accidents in driving simulation as a promising tool to assess excessive daytime sleepi


  • Open Access

    Metabolomics-based Sleepiness Markers for Risk Prevention and Traffic Safety (ME-SMART): a monocentric, controlled, randomized, crossover trial

    by Michael Scholz, Stefan Lakaemper, Kristina Keller, Akos Dobay, Andrea Eva Steuer, Hans-Peter Landolt, Thomas Kraemer

    Background: Too little sleep and the consequences thereof are a heavy burden in modern societies. In contrast to alcohol or illicit drug use, there are no quick roadside or workplace tests for objective biomarkers for sleepiness. We hypothesize that changes in physiological functions (such as sleep–wake regulation) are reflected in changes of endogenous metabolism and should therefore be detectable as a change in metabolic profiles. This study will allow for creating a reliable and objective panel of candidate biomarkers being indicative for sleepiness and its behavioral outcomes. Methods: This is a monocentric, controlled, randomized, crossover, clinical study to detect potential biomarkers. Each of the anticipated 24 participants will be allocated in randomized order to each of the three study arms (control, sleep restriction, and sleep deprivation). These only differ in the amount of hours slept per night. In the control condition, participants will adhere to a 16/8 h wake/sleep regime. In both sleep restriction and sleep deprivation conditions, participants will accumulate a total sleep deficit of 8 h, achieved by different wake/sleep regimes that simulate real-life scenarios. The primary outcome is changes in the metabolic profile (i.e., metabolome) in oral fluid. Secondary outcome measures will include driving performance, psychomotor vigilance test, d2 Test of Attention, visual attention test, subjective (situational) sleepiness, electroencephalographic changes, behavioral markers of sleepiness, changes in metabolite concentrations in exhaled breath and finger sweat, and correlation of metabolic changes among biological matrices. Discussion: This is the first trial of its kind that investigates complete metabolic profiles combined with performance monitoring in humans over a multi-day period involving different sleep–wake schedules. Hereby, we aim to establish a candidate biomarker panel being indicative for sleepiness and its behavioral outcomes. To date, there are no robust and easily accessible biomarkers for the detection of sleepiness, even though the vast damage on society is well known. Thus, our findings will be of high value for many related disciplines. Trial registration: ClinicalTrials.gov Identifier NCT05585515, released on 18.10.2022; Swiss National Clinical Trial Portal SNCTP000005089, registered on 12 August 2022.


  • Open Access

    Strong evidence for age as the single most dominant predictor of medically supervised driving test—mini mental status test outcomes provide only weak but significant moderate additional predictive value

    by Yannik Isler, Simon Schwab, Regula Wick, Stefan Lakämper

    With age, medical conditions impairing safe driving accumulate. Consequently, the risk of accidents increases. To mitigate this risk, Swiss law requires biannual assessments of the fitness to drive of elderly drivers. Drivers may prove their cognitive and physical capacity for safe driving in a medically supervised driving test (MSDT) when borderline cases, as indicated by low performance in a set of four cognitive tests, including e.g. the mini mental status test (MMST). Any prognostic, rather than indicative, relations for MSDT outcomes have neither been confirmed nor falsified so far. In order to avoid use of unsubstantiated rules of thumb, we here evaluate the predictive value for MSDT outcomes of the outcomes of the standard set of four cognitive tests, used in Swiss traffic medicine examinations. We present descriptive information on age, gender and cognitive pretesting results of all MSDTs recorded in our case database from 2017 to 2019. Based on these retrospective cohort data, we used logistic regression to predict the binary outcome MSDT. An exploratory analysis used all available data (model 1). Based on the Akaike Information Criterion (AIC), we then established a model including variables age and MMST (model 2). To evaluate the predictive value of the four cognitive assessments, model 3 included cognitive test outcomes only. Receiver operating characteristics (ROC) and area under the curve (AUC) allowed evaluating discriminative performance of the three different models using independent validation data. Using N = 188 complete data sets of a total of 225 included cases, AIC identified age (p < 0.0008) and MMST (p = 0.024) as dominating predictors for MSDT outcomes with a median AUC of 0.71 (95%-CI 0.57–0.85) across different training and validation splits, while using the four cognitive test results exclusively yielded a median AUC of 0.55 (95%-CI 0.40–0.71). Our analysis provided strong evidence for age as the single most dominant predictor of MSDT outcomes. Adding MMST provides only weak additional predictive value for MSDT outcomes. Combining the results of four cognitive test used as standard screen in Swiss traffic medicine alone, proved to be of poor predictive value. This highlights the importance of MSDTs for balancing between the mitigation of risks by and the right to drive for the elderly.